Study of E7386 in Participants With Selected Advanced Neoplasms
← catalyst calendarNCT03264664 · readout in 224 d
Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
10
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-07-27 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2017-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Neoplasms
Intervention
- Drug: E7386
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Dose-limiting Toxicities (DLTs)
measured Cycle 1 (28 days)
Recommended Phase 2 Dose (RP2D)
measured Cycle 1 (28 days)
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
measured From the date of first dose of study drug up to 28 days after administration of study drug (up to approximately 6 years and 10 months)
Publications
- PMID 42243349 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed